Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Thyroid cancer
Stage/Subtype:  recurrent thyroid cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-21 of 21 for your search:
Start Over
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Sapanisertib in Treating Patients with Newly Diagnosed or Refractory/Metastatic Anaplastic Thyroid Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-223, NCI-2015-01607, NCT02244463
Genetically Modified Lymphocytes in Treating Patients with Thyroglobulin-Expressing Thyroid Cancer That Is Recurrent or Metastatic and Cannot Be Removed by Surgery
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 15-C-0090, NCI-2015-00499, 1412-1366, 150090, 342570, 8340274, P141702, RD14-XII-05, NCT02390739
A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PLX120-03, NCI-2015-00720, NCT02428712
Pioglitazone Hydrochloride in Treating Patients with Thyroid Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UMCC 2011.097, NCI-2012-01918, 2011.097, HUM00049615, NCT01655719
Biomarkers in Predicting Response in Patients with Locally Advanced Thyroid Cancer Receiving Vemurafenib before Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2012-0471, NCI-2012-02171, 00000363, NCT01709292
Dabrafenib with or without Trametinib in Treating Patients with Recurrent Thyroid Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU 12064, NCI-2012-01700, 2012C0074, NCCNGSK20008, NCT01723202
Vaccine Therapy in Treating Patients with Recurrent or Metastatic Medullary Thyroid Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-C-0095, NCI-2013-01587, 1301-1199, GI-6207, GI-6207-02, P11934, RD-13-I-10, NCT01856920
Cabozantinib-S-Malate as First-Line Therapy in Treating Patients With Radioiodine-Refractory Thyroid Cancer That is Metastatic or Cannot Be Removed By Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 28313, NCI-2014-00171, 818408, UPCC 28313, NCT02041260
Sorafenib Tosylate with or without Everolimus in Treating Patients with Advanced, Radioactive Iodine Refractory Thyroid Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: A091302, NCI-2014-00623, NCT02143726
Trametinib in Increasing Tumoral Iodine Incorporation in Patients with Recurrent or Metastatic Thyroid Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9446, NCI-2014-01106, 13-157, NCT02152995
Phase II Study of Tipifarnib in Advanced Cancers With HRAS Mutations
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: KO-TIP-001, NCI-2015-01835, NCI-2015-00949, NCT02383927
Iodine I-131 with or without Selumetinib in Treating Patients with Recurrent or Metastatic Thyroid Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RU241306I, NCI-2015-00277, 14-008494, NCT02393690
Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LOXO-TRK-15002, NCI-2015-01947, NCT02576431
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3475-158, NCI-2015-02278, 163196, 2015-002067-41, NCT02628067
Regorafenib in Treating Patients with Metastatic Medullary Thyroid Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-350, NCI-2016-00333, NCT02657551
Dabrafenib and Lapatinib Ditosylate in Treating Patients with Refractory Thyroid Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9354, NCI-2013-01748, 13-061, NCT01947023
Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E7080-A001-109, NCI-2016-00275, NCT02686164
Dabrafenib and Radioactive Iodine in Treating Patients With Papillary Thyroid Carcinoma
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-337, NCI-2012-00817, NCT01534897
An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Status: Not yet active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: E7080-G000-398, NCI-2014-01802, NCT02211222
Start Over